A recent independent analysis of 47 sleep-focused cannabinoid products has shed light on the efficacy and quality of formulations combining Delta-9 THC and CBN (cannabinol), particularly highlighting BudPop’s Delta-9 + CBN gummies. This assessment comes at a time when 50 to 70 million Americans face sleep-related challenges, signaling a growing consumer interest in plant-based wellness solutions as alternatives to traditional pharmaceuticals.

The analysis revealed that Delta-9 + CBN gummies significantly improved subjective sleep quality compared to placebo, as evidenced by a 2025 meta-analysis involving over 1,000 participants. With the cannabinoid sleep segment experiencing 18% year-over-year growth, these gummies are gaining traction due to their discrete, portion-controlled dosing and predictable effects, which typically last between 4 to 8 hours. The combination of Delta-9 THC, which may facilitate quicker sleep onset, and CBN, which is being studied for its potential to prolong sleep duration, reflects an innovative approach to addressing multifaceted sleep issues.

This trend toward cannabinoid formulations underscores a shift in research paradigms and therapeutic strategies in the sleep aid market. As the global sleep aid market is projected to reach $162 billion by 2034, the increasing availability and consumer preference for CBN-dominant and combination formulations could accelerate the timeline for drug development in this space. Furthermore, ongoing clinical trials are crucial for establishing evidence-based recommendations, particularly regarding dosing and long-term safety. As the market evolves, a focus on product transparency and rigorous testing will be essential for ensuring consumer trust and efficacy in cannabinoid-based sleep aids.

Source: globenewswire.com